| Literature DB >> 26561831 |
María E Mejía-León1, Ana M Calderón de la Barca2.
Abstract
Type 1 diabetes (T1D) is the second most frequent autoimmune disease in childhood. The long-term micro- and macro-vascular complications of diabetes are associated with the leading causes of disability and even mortality in young adults. Understanding the T1D etiology will allow the design of preventive strategies to avoid or delay the T1D onset and to help to maintain control after developing. T1D development involves genetic and environmental factors, such as birth delivery mode, use of antibiotics, and diet. Gut microbiota could be the link between environmental factors, the development of autoimmunity, and T1D. In this review, we will focus on the dietary factor and its relationship with the gut microbiota in the complex process involved in autoimmunity and T1D. The molecular mechanisms involved will also be addressed, and finally, evidence-based strategies for potential primary and secondary prevention of T1D will be discussed.Entities:
Keywords: Bacteroides; Type 1 diabetes; autoimmunity; diet; dysbiosis; gut microbiota
Mesh:
Year: 2015 PMID: 26561831 PMCID: PMC4663589 DOI: 10.3390/nu7115461
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Comparison of microbiota composition in humans with autoimmunity and T1D.
| Country/Ethnicity | Diagnostic ( | Age in Years | Microbiota Diversity in Autoimmunity/T1D | Microbiota Relative Abundance in Autoimmunity/T1D | Other Findings |
|---|---|---|---|---|---|
| Finland (DIPP Study)/Caucasians [ | β-cell AI (4) | 0–2 | Reduced | F/B ratio ↓ | Non-butyrate producers avoid optimal mucine synthesis in T1D-associated autoimmunity. |
| Spain/Caucasians [ | T1D at onset (16) | 7.16 ± 0.72 | Similar to the control group ( | F/B ratio ↓ | Microbiota differences were associated with glycemic level. |
| Finland (FINDIA and TRIGR studies)/Caucasians [ | β-cell AI (18) | FINDIA/TRIGR: | Reduced | F/B ratio ↓ | The abundance of lactate- and butyrate-producing bacteria was inversely related to the number of β cell autoantibodies. |
| Mexico/Mestizos [ | T1D at onset (8) | 12.3 ± 0.64 | Similar to the control group ( | Unaltered F/B ratio. | The glycemic control in the T1D ≥ 2 years treated group partially normalizes the microbiotal profile towards |
| Finland (DIPP Study)/Caucasians [ | High risk cohort (76): | 0–2 | Reduced | F/B ratio ↓ | |
| Finland, Estonia (DIABIMMUNE Study)/Caucasians [ | High risk cohort (33): | 0–3 | Reduced | Increase in: | Decreased community diversity occurs after seroconversion but before onset of T1D. |
| USA/White Americans (TRIALNET Study) [ | β-cell AI (21) | 4–49 | Similar to the control group ( | Increase in: | The microbiomes of β-cell AI and seroneg. FDRs clustered together but separate from those of T1D at onset and HC. |
T1D: Type-1 Diabetes; β-cell AI: β-cell autoimmunity; F/B ratio: Firmicutes/Bacteroidetes ratio; HC: Healthy controls; FDR: First degree relatives. DIPP: Diabetes Prediction and Prevention; FINDIA: Finnish Dietary Intervention Trial for the Prevention of Type 1 Diabetes; TRIGR: Trial to Reduce Type 1 Diabetes in the Genetically at Risk; TRIALNET: Type 1 Diabetes TrialNet; * indicate that these findings (Increase in: Bacteroides, Decrease in: Prevotella) were only detected in seropositive subjects from the TRIALNET study with multiple versus one autoantibody and there were not considered the seronegative first degree relatives included in the original study design.
Figure 1Diet and microbiota associated mechanisms in autoimmunity and type 1 diabetes (T1D) development.